Poster Session A

Poster Session A
Wednesday, December 1
4:35 p.m.-6:30 p.m.

In alphabetical order, not board assignment order

Antibodies in Cancer Immunity
• Hypoxic exposure as a novel strategy to identify tumor-associated antigens in prostate cancer. Christian R. Gomez, Farhad Kosari, Claire A. Schreiber, Gaylord J. Knutson, George Vasmatzis, Stanimir Vuk-Pavlovic. Mayo Clinic, Rochester, MN
• Optimization of monoclonal antibodies for antitumor efficacy. Yong Tang1, Yu Zhou2, Wei Xu1, Louis M. Weiner1, James D. Marks2. 1Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 2 University of California, San Francisco, CA
• Targeting human CEACAM1 by novel melanoma immunotherapy. Rona Ortenberg1, Sivan Sapoznik2, Liat Hershkoviz2, Michal J. Besser2, Jacob Schachter2, Gal Markel1, Eyal Greenberg1, Yael Nemlih-Wolff1. 1Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 2Ella Institute of Melanoma, Sheba Medical Center, Ramat Gan, Israel

Cancer Vaccines
• Dendritic cell differentiation blockade in CD14+ monocytes in glioblastoma, non-Hodgkin’s lymphoma and prostate cancer patients. Yi Lin, Michael Gustafson, Peggy Bulur, Stanimir Vuk-Pavlovic, Thomas E. Witzig, Dennis Gastineau, Allan B. Dietz. Mayo Clinic, Rochester, MN
• Heat shock induction of tumor-derived danger signals mediate rapid monocyte differentiation to clinically effective dendritic cells. Flavio Salazar-Onfray, Mercedes N. Lopez. University of Chile, Santiago, Chile
• Immunization with CMV-based vector encoding CD8 T cell epitope from PSA avoids induction of regulatory T cells and results in CD8 T cell memory inflation and protection from tumor challenge. Elena N. Klyushnenkova1, Diana V. Kouiavskaia1, Patrizia Caposio2, Sara Boto2, Richard B. Alexander3, Michael Jarvis2. 1University of Maryland School of Medicine, Baltimore, MD, 2Oregon Health Science University, Portland, OR, 3VA MHCS, Baltimore, MD
• IRX-2, a novel immunotherapeutic, enhances dendritic cell functions. Bastian Schilling1, Malgorzata Harasymczuk1, Patrick J. Schuler1, James E. Egan2, Theresa L. Whiteside1. 1University of Pittsburgh, Department of Pathology and University of Pittsburgh Cancer Institute, Pittsburgh, PA, 2IRX Therapeutics Inc., Farmingdale, NY
• Lentiviral transduced dendritic cells targeting survivin antigen are effective to induce anti-neuroblastoma immune response. Elisa Berger1, Holger Lode2, Rocio Soldati1, Ana Zenclussen3, Gerhard Jorch1, Stefan Fest1. 1Otto-von-Guericke University, Department of Pediatrics, Magdeburg, Germany, 2University of Greifswald, Department of Pediatric Hematology and Oncology, Greifswald, Germany, 3Otto-von-Guericke University, Experimental Gynecology, Magdeburg, Germany
• MHC II-restricted peptides derived from invariant chain negative breast cancer cell-based vaccines activate healthy donor T cells. Olesya Y. Chornoguz, Lydia Grmai, Alexei Gapeev, Suzanne Ostrand-Rosenberg, Michael O'Neill. University of Maryland Baltimore County, Baltimore, MD
• Survival after immunotherapy of malignant brain tumors is correlated to both tumor cell proliferation and pre-/posttreatment immune responses. Peter Siesjö, Edward Visse, Anna Darabi. Department of Clinical Science, Lund, Sweden
• The effect of a Listeria monocytogenes-based vaccine for prostate cancer on intratumor suppressor cells. Reshma Singh, Anu Wallecha, John Rothman. Advaxis, Inc., North Brunswick, NJ

Combined Therapy
• Boosting antitumor immunity by combining gp96-Ig vaccination and Fc-mTL1A fusion protein. Samia Q. Khan, Vadim Deyev, Podack R. Eckhard. Miller School of Medicine, University of Miami, Miami, FL
• CD44 as a target for therapy in head and neck squamous cell carcinoma (HNSCC). Aymee Perez, David Neskey, Lutecia Pereira, Judy Wen, Jarrard W. Goodwin, Joyce Slingerland, Elizabeth J. Franzmann. University of Miami, Miami, FL
• Immunotherapy enhances tumor-specific CD8+ T cell responses induced by nitroreductase prodrug activation gene therapy. Asmaa Salman1,2, Peter F. Searle2. 1National Research Centre, Cairo, Egypt, 2School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
• Vaccination with lymphoma cells secreting gp96-Ig leads to the generation and expansion of CD8 effector cells in autologous HSCT recipients and is enhanced by IL-2 antibody-cytokine complex. Robert G. Newman, Eckhard R. Podack, Robert B. Levy. University of Miami, Miami, FL

Epigenetic Regulation of Tumor Growth and Immune Recognition
• Differential effects on tumor growth with Ikkβ deletion in tumor versus myeloid cells. Jinming Yang, Tammy Sobolik-Delmaire, Linda W. Horton, Ann Richmond. Vanderbilt University, Nashville, TN
• MUC1 regulates interleukins expression in cancer cells. Sandra Cascio, Lixin Zhang, Pamela Beatty, Olivera Finn. University of Pittsburgh, Pittsburgh, PA

Harnessing the Immune System to Prevent and Fight Disease
• A new type I NKT cell agonist induces tumor immunity through an unconventional pathway. Masaki Terabe1, Jessica J. O'Konek1, Deborah Stewart Khursigara1, Petr Illarinov2, Elena Ambrosino1, Liat Izhak1, Bernard F. Castillo, II3, Maryam Raju3, Maryam Khalili3, Hee-Yong Kim4, Amy R. Howell3, Gurdyal S. Besra2, Steven A. Porcelli5, Jay A. Berzofsky1. 1National Cancer Institute, Bethesda, MD, 2University of Birmingham, Birmingham, United Kingdom, 3University of Connecticut, Storrs, CT, 4National Institute on Alcohol Abuse and Alcoholism, Rockville, MD, 5Albert Einstein College of Medicine, New York, NY
• Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants. Karen M. Kaluza, Jill Thompson, Heather Flynn Gilmer, Darlene Knutson, Richard Vile. Mayo Clinic, Rochester, MN
• Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of the breast cancer cells. Anandi Sawant, Jonathan Hensel, Diptiman Chanda, Selvarangan Ponnazhagan. University of Alabama at Birmingham, Birmingham, AL
• Epidermal growth factor receptor synthetic peptides induce immune and clinical responses in advanced ovarian cancer patients. Jose V. Torres1, Juan P. Marquez1, Murray B. Gardner1, Erik Ramos1, Fernando Durazo2, Ramon Cabello3, Luis Salguero3, Lucero Pedro3. 1University of California, Davis, CA, 2Saide-Marcos Ovarian and Breast Cancer Foundation, Monterrey, Nuevo Leon, Mexico, 3Sonora Cancer Research Center, Ciudad Obregon, Sonora, Mexico
• Th-1 lymphocytes promote dendritic cell tumoricidal activity. Collin J. LaCasse1, Nona Janikashvili2, Emmanuel Katsanis1, Nicolas Larmonier1. 1University of Arizona, Tucson, AZ, 2Universite de Bourgogne, Dijon, France

Premalignant Lesions and Prevention
• Spatial and temporal regulation of CXCR3 chemokine production and CD8 T cell infiltration in the metastatic melanoma microenvironment. David W. Mullins, Eleanor Clancy-Thompson, Sarah J. Conine. University of Virginia, Charlottesville, VA

Regulation of Immune Responses in Cancer
• Adenosine and A2B adenosine receptor in regulation of tumor-infiltrating myeloid cells. Sergey V. Ryzhov, Sergey V. Novitskiy, Anna E. Goldstein, Igor Feoktistov, Mikhail M. Dikov. Vanderbilt University, Nashville, TN
• Alterations in the immune responses of animals with recurrent tumors may explain the failure of adjuvant immunotherapy. Jarrod D. Predina1, Zvi G. Fridlender2, Brendan F. Judy1, Aaron Blouin1, Veena Kapoor1, Natalie Ridge1, Steven M. Albelda1, Sunil Singhal1. 1University of Pennsylvania School of Medicine, Philadelphia, PA, 2Hadassah-Hebrew University Medical Center, Jerusalem, Israel
• Defects of HLA class II antigen expression and infiltration with CD4-positive T cells in MSI-H colorectal cancer. Matthias Kloor1, Eva Maria Surmann1, Anita Voigt1, Sara Michel1, Kathrin Bauer1, Soldano Ferrone2, Magnus von Knebel Doeberitz1. 1University Hospital Heidelberg, Heidelberg, Germany, 2University of Pittsburgh, Pittsburgh, PA
• Galectin-1 inhibitory disaccharide affects tumor angiogenesis and promotes CD8+ lymphocyte infiltration associated with reduced tumor growth in mice. Koichi Ito1, Stacy Scott2, Lan-feng Dong1, Jiri Neuzil1, Helen Blanchard2, Stephen Ralph1. 1School of Medical Science, Griffith University, Southport, Australia, 2Institute for Glycomics, Griffith University, Southport, Australia
• Glioma cancer stem cells induce immune suppressive macrophages. Adam Wu, Jun Wei, Lingyuan Kong, Yongtao Wang, Waldemar Priebe, Raymond Sawaya, Amy Heimeberger. University of Texas MD Anderson Cancer Center, Houston, TX
• Immunotherapy using wild-type tumor cells and COX-2 inhibition significantly increases the survival of glioma-bearing rats and induces a persistent memory response. Sofia Eberstål, Sara Fritzell, Wiaam Badn, Anna Darabi, Edward Visse, Peter Siesjö. Lund University, Lund, Sweden
• Low levels of LMP2 and LMP7 are associated with reduced susceptibility of tumor cells to cytotoxic T cell-mediated lysis. Andrea M. Henle, Courtney L. Erskine, Keith L. Knutson. Mayo Clinic, Rochester, MN
• Molecular characterization of tumor associated neutrophils. Zvi G. Fridlender1,2, Natalie Ridge2, Sunil Singhal2, Veena Kapoor2, Jing Sun2, Wenhwai Horng3, Guanjun Cheng2, Gil Fridlender1, Scott Worthen2, Steven M. Albelda2. 1Hadassah-Hebrew University Medical Center, Jerusalem, Israel, 2University of Pennsylvania, Philadelphia, PA, 3The Wistar Institute, Philadelphia, PA
• NK cell-dependent suppression of tumor growth and metastasis in CXCL14/BRAK transgenic mice. Ryu-Ichiro Hata1, Kazuhito Izukuri1, Yasumasa Kato2. 1Kanagawa Dental College, Yokosuka, Japan, 2Ohu University School of Dentistry, Koriyama, Japan
• NY-ESO-1-specific CD8 T-cell response in NY-ESO-1 seropositive metastatic melanoma patients treated with ipilimumab correlates with clinical benefit. Jianda Yuan1, Brian A. Ginsberg1, Sacha Gnjatic2, Matthew Adamow1, Erika Ritter2, Teresa Rasalan1, Humilidad F. Gallardo1, Yinyan Xu1, Evelina Pogoriler1, Stephanie Terzulli1, Katherine S. Panageas3, Gerd Ritter2, Lloyd Old2, James P. Allison1, Jedd D. Wolchok1. 1Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY, 2Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY, 3Memorial Sloan-Kettering Cancer Center Department of Biostatistics, New York, NY
• Regulation of CD8 T memory cells by RAD001 in an in vitro model. Melanie Mediavilla-Varela, Kimberly Luddy, Scott J. Antonia. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
• Regulatory T cells are dependent on PI3K pathway allowing for their selective inhibition in vivo. Raed N. Samara, Yujun Dong, Maher Abdalla, Mikayel Mkrtichyan, Laurent Ozbun, Yufei Jiang, Jiahua Qian, Samir Khleif. National Cancer Institute, Bethesda, MD
• Targeting monocyte chemotactic proteins (MCPs) with synthesis inhibitors induces cancer tumor regression in vivo. Valeria Di Dato1, Daniela De Martino1, Viviana Vastolo1, Luigi Navas2, Beatrice Garrone3, Giorgia Mangano3, Giuseppe Biondi3, Angelo Guglielmotti3, Massimo Zollo2. 1Centro di Ingegneria Genetica e Biotecnologia Avanzate (CEINGE), Naples, Italy, 2University of Naples "Federico II" and Centro Ingegneria Genetica e Biotecnologia Avanzate (CEINGE), Naples, Italy, 3Angelini Research Center, Santa Palomba-Pomezia, Rome, Italy
• Testing the NKT cell hypothesis in multiple myeloma and myelodysplastic syndrome patients. Stuart P. Berzins1, Paul Neeson2, Dale I. Godfrey1, Angela C. Chan1, Miles H. Prince2, David Ritchie2, Kellie Tainton2, Hang Quach2, Edwin Leeansyah1. 1University of Melbourne, Parkville, Australia, 2Peter MacCallum Cancer Centre, Melbourne, Australia
• The identification of two functionally distinct subsets (Treg and Teff) within the human CD4+CD39+ T cell population. Patrick J. Schuler1, Bastian Schilling1, Malgorzata Harasymczuk1, Sven Brandau2, Stephan Lang2, Thomas K. Hoffmann2, Theresa L. Whiteside1. 1University of Pittsburgh Cancer Institute, Pittsburgh, PA, 2HNO-Klinik Universitaet Duisburg-Essen, Essen, Germany
• The role of different subtypes of macrophages in colorectal cancer. Sofia Edin1, Maria L. Henriksson1, Anna M. Dahlin1, Jörgen Rutegård2, Åke Öberg2, Per-Arne Oldenborg3, Richard Palmqvist1. 1Medical Biosciences, Pathology, Umeå University, Umeå, Sweden, 2Surgical and Perioperative Sciences, Surgery, Umeå University, Umeå, Sweden, 3Integrative Medical Biology, Histology and Cellular Biology, Umeå University, Umeå, Sweden
• The role of heme oxygenase-1 as a modulator of the anti-neuroblastoma immune response. Rocio Soldati1, Elisa Berger1, Ana Zenclussen2, Gerhard Jorch1, Stefan Fest1. 1Otto-von-Guericke University, Department of Pediatrics, Magdeburg, Germany, 2Otto-von-Guericke University, Experimental Gynecology, Magdeburg, Germany

Other
• ATF3, a hub of the stress-response network, promotes a systemic host environment that enhances cancer metastasis. Christopher C. Wolford, Stephen J. McConoughey, Swati Jalgaonkar, Xin Yin, Tsonwin Hai. The Ohio State University, Columbus, OH
• Epithelial FVB MMTV-Neu primary mammary tumor cells have enhanced tumorigenicity compared to fibroblastoid tumor cells that express mesenchymal and metastasis-associated genes. Jill A. Gershan, Bryon D. Johnson, Katie A. Palen, James J. Weber. Medical College of Wisconsin, Milwaukee, WI
• In vivo imaging reveals how blood supply shapes the regional progress of tumor cell cytotoxicity as cytotoxic T cells spread through melanomas. Yoav Manaster1, Zohar Shipony1, Bruria Shalmon2, Avivi Camila2, Iris Barshack2, Michal J. Besser3, Guy Shakhar1. 1Weizmann Institute, Rehovot, Israel, 2Department of Pathology, Sheba Medical Center, Ramat Gan, Israel, 3Ella Institute, Sheba Medical Center, Ramat Gan, Israel
• Tumor-associated macrophages regulate tumorigenicity and anticancer drug sensitivity of cancer stem cells. Glenn Dranoff1, Masahisa Jinushi2. 1Dana-Farber Cancer Institute, Boston, MA, 2Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
• Tumor-infiltrating T cells, the CpG island methylator phenotype (CIMP), and colorectal cancer patient survival. Anna M. Dahlin, Maria L. Henriksson, Bethany Van Guelpen, Roger Stenling, Åke Öberg, Jörgen Rutegård, Richard Palmqvist. Umeå University, Umeå, Sweden